Judith Villablanca

Exploring the impact of innovative treatment strategies on high-risk neuroblastoma, Dr. Judith G. Villablanca is a Clinical Professor of Pediatrics (Part-Time) at the Keck School of Medicine of USC. Her affiliation with Children's Hospital Los Angeles allows her to work closely with patients and fellow researchers, driving forward the understanding and treatment of this challenging pediatric cancer. Dr. Villablanca's research is primarily centered on high-risk neuroblastoma, a focus that has led her to investigate cutting-edge therapies such as lorlatinib and chemotherapy in cases of ALK-driven refractory neuroblastoma. Her dedication to improving patient outcomes is evident in her work evaluating treatment eligibility and response criteria for those with refractory, relapsed, or progressive forms of the disease. Throughout her career, Dr. Villablanca has made significant contributions to the field through numerous publications. These works delve into the genetic underpinnings of neuroblastoma, exploring how specific genes influence treatment responses and outcomes. Her research not only advances scientific understanding but also informs clinical practices, offering hope to patients and families affected by this aggressive cancer. In addition to her research endeavors, Dr. Villablanca is committed to mentoring the next generation of pediatric oncologists and researchers. Her role at the Keck School of Medicine of USC involves guiding students and young professionals as they navigate the complexities of pediatric cancer treatment and research. Dr. Villablanca's work is characterized by a deep commitment to translating scientific discoveries into tangible improvements in patient care. Her efforts continue to shape the landscape of neuroblastoma treatment, providing new avenues for hope and healing for children facing this formidable disease.